Search

Your search keyword '"Wyde, Philip R."' showing total 159 results
Start Over Author "Wyde, Philip R."
159 results on '"Wyde, Philip R."'

19. Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo

Author

Yu, Kuo-Long, primary, Wang, Xiangdong Alan, additional, Civiello, Rita L., additional, Trehan, Ashok K., additional, Pearce, Bradley C., additional, Yin, Zhiwei, additional, Combrink, Keith D., additional, Gulgeze, H. Belgin, additional, Zhang, Yi, additional, Kadow, Kathleen F., additional, Cianci, Christopher W., additional, Clarke, Junius, additional, Genovesi, Eugene V., additional, Medina, Ivette, additional, Lamb, Lucinda, additional, Wyde, Philip R., additional, Krystal, Mark, additional, and Meanwell, Nicholas A., additional

Published
2006
Full Text
View/download PDF

25. Common Emergence of Amantadine‐ and Rimantadine‐Resistant Influenza A Viruses in Symptomatic Immunocompromised Adults

Author

Englund, Janet A., primary, Champlin, Richard E., additional, Wyde, Philip R., additional, Kantarjian, Hagop, additional, Atmar, Robert L., additional, Tarrand, Jeffrey, additional, Yousuf, Hassan, additional, Regnery, Helen, additional, Klimov, Alexander I., additional, Cox, Nancy J., additional, and Whimbey, Estella, additional

Published
1998
Full Text
View/download PDF

49. An Aged Mouse Model for RSV Infection and Diminished CD8+CTL Responses1

Author

Zhang, Yongxin, Wang, Ying, Gilmore, Xyanthine, Xu, Keyi, Wyde, Philip R., and Mbawuike, Innocent N.

Abstract

Recent studies indicate that respiratory syncytial virus (RSV), like influenza, causes significant morbidity and mortality among elderly persons. There are currently no animal models to study the effects of aging on RSV disease and immunity. This manuscript provides an initial description of such a model. Aged and young BALB/c mice (22-24 and 2-4 months, respectively) were infected with 104TCID50of RSV A2. RSV was detected by culture in lung and nose wash specimens obtained 4-6 days following infection at a slightly higher titer in old mice in comparison with young mice. RT-PCR assay detected RSV in the lungs and nose washes of all mice on 4, 8, and 21 days postinoculation, with only a slightly less frequency in young mice. Splenic lymphocytes from old mice exhibited significantly lower RSV-specif ic MHC class I-restricted CD8+CTL responses (P < 0.01-0001), and reduced IFN-production (P < 0.03) than young mice. Conversely, IL-4 production was somewhat elevated in old mice. These results demonstrate diminished RSV virus-specific CD8+CTL responses and IFN-γ production in old mice in comparison with young. It is speculated that the deficient RSV-specific CTL responses may account for the Increased morbidity and mortality from RSV Infections in elderly persons. Although detailed hlstopathological, virological, and immunological analyses are incomplete at present, the old BALB/c RSV infection model described provides an opportunity to evaluate the role of CD8+ CTL and cytokines in RSV disease in aging.

Published
2002
Full Text
View/download PDF

50. Immunogenicity and protection in mice given inactivated influenza vaccine, MPL, QS-21 or QS-7

Author

Wyde, Philip R., Guzman, Efrain, Gilbert, Brian E., and Couch, Robert B.

Abstract

Background : Monophosphoryl lipid A (MPL), QS-21 and QS-7 were evaluated in mice for their ability to increase the immunogenicity and protective efficacy of formalin-inactivated (FI) influenza A/Texas/91 virus vaccine. Freund's incomplete adjuvant (FIA) was used as a positive control. Methods : Mice were inoculated twice, 28 days apart, either intramuscularly (I.M.) with vaccine mixed with phosphate buffered saline, FIA, MPL or QS21, or intranasally (I.N.) with vaccine containing QS-21 or QS-7. The mice were bled on days 0, 28 and 49 and challenged I.N. on this last day with live virus. Four days later, the lungs from each animal were assessed for influenza virus. All sera were tested for virus-specific neutralizing (Nt), hemagglutination inhibiting (HI) and ELISA antibodies. Studies to account for the mechanism(s) of adjuvant activity have been initiated. Results : FIA, MPL and QS-21 all enhanced the production of virus-specific antibodies and increased protection from pulmonary virus infection following I.M. administration. Maximal adjuvanticity occurred in groups inoculated with "low" doses of vaccine and in groups administered vaccine mixed with QS-21. Both QS adjuvants exhibited significant adjuvant activity following I.N. inoculation. Protection correlated best with levels of virus-specific serum Nt and HI antibodies. Conclusions : The present studies support continued development of adjuvants for inactivated influenza virus vaccines.

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results